Voyager extends cash runway with $175M up front in Neurocrine deal

Voyager more than doubled its cash position after announcing a new deal granting Neurocrine worldwide rights to its preclinical GBA1 gene therapy program for Parkinson’s disease. Voyager will receive $175 million up front, including a $39 million equity investment at $8.88 per share, a 28% premium over the biotech’s previous close of $6.96.

Voyager Therapeutics Inc. (NASDAQ:VYGR) has an option to co-develop and co-commercialize the gene therapy on a 50/50 cost-and-profit sharing basis after Phase I data. If the option isn’t exercised, Voyager would be eligible for up to $4.2 billion in milestones, including $1.5 billion in development milestones, plus royalties. ...